title: Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
abstract: We previously showed that a peptide (PR1) derived from the primary granule enzyme proteinase 3 induced peptide specific cytotoxic T lymphocytes (CTL) in a normal HLA-A2.1+ individual. These CTL showed HLA-restricted cytotoxicity to myeloid leukemias (which overexpress proteinase 3). To further investigate their antileukemic potential, we studied the ability of PR1-specific CTL, derived from two HLA-A2.1+ normal individuals, to inhibit colony-forming unit granulocyte-macrophage (CFU-GM) from normal and leukemic individuals. CTL from 20 day PR1 peptide-pulsed lymphocyte cultures showed 89% to 98% HLA-A2.1-restricted colony inhibition of chronic myeloid leukemia targets. Colony formation in normal HLA-A2.1+ bone marrow or HLA-A2.1- CML cells was not inhibited. Sequencing of the exon encoding PR1 showed that colony inhibition was not caused by polymorphic differences in proteinase 3 between effectors and targets. Analysis by flow cytometry showed that proteinase 3 was overexpressed in the leukemia targets compared with normal marrow targets (median channel fluorescence 1,399 v 298, P = .009). These results show that PR1-specific allogeneic T cells preferentially inhibit leukemic CFU-GM based on overexpression of proteinase 3, and that proteinase 3-specific CTL could be used for leukemia-specific adoptive immunotherapy.
authors.affiliation: Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Molldrem
authors.forename: E
authors.initials: E
authors.lastname: Clave
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Jiang
authors.forename: D
authors.initials: D
authors.lastname: Mavroudis
authors.forename: A
authors.initials: A
authors.lastname: Raptis
authors.forename: N
authors.initials: N
authors.lastname: Hensel
authors.forename: V
authors.initials: V
authors.lastname: Agarwala
authors.forename: A J
authors.initials: AJ
authors.lastname: Barrett
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D005091:Exons / Q000235:genetics; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000473:pathology; D053146:Myeloblastin; D009363:Neoplasm Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D014411:Neoplastic Stem Cells / Q000201:enzymology / Q000276:immunology*; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D012697:Serine Endopeptidases / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
chemical_list: D015789:HLA-A2 Antigen; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D012697:Serine Endopeptidases; D053146:Myeloblastin